EXOZ NASDAQ
eXoZymes, Inc.
1W: -7.7%
1M: -15.0%
3M: -29.1%
YTD: -47.5%
1Y: -58.8%
$5.77
+0.01 (+0.17%)
Weekly Expected Move ±7.5%
$5
$5
$6
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$53.6M
52W Range4.35-18.4
Volume2,104
Avg Volume8,786
Beta3.15
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael Heltzen
Employees32
SectorHealthcare
IndustryBiotechnology
IPO Date2024-11-13
Websiteexozymes.com
750 Royal Oaks Drive
Monrovia, CA 91016
US
Monrovia, CA 91016
US
626 415 1488
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Latest News
eXoZymes reports Q2 results
eXoZymes reports FY results
Earnings Scheduled For March 31, 2026
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Nawaz Fouad | A-Award | 45,000 | $6.28 | 2026-09-14 |
| Heltzen Michael | P-Purchase | 4 | $7.58 | 2026-08-26 |
| Heltzen Michael | P-Purchase | 251 | $7.35 | 2026-08-26 |
| Heltzen Michael | P-Purchase | 250 | $7.60 | 2026-08-26 |
| Heltzen Michael | P-Purchase | 250 | $7.52 | 2026-08-25 |